Protalix BioTherapeutics IncFind Ratings Reports
PROTALIX BIOTHERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. PROTALIX BIOTHERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.99 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 191.57% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||2.08||0.0|
|Net Income ($mil)||-2.62||72.9|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||63.76||76.75|
|Total Assets ($mil)||82.25||97.25|
|Total Debt ($mil)||77.52||72.1|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||29.94||0.0|
|Return on Assets||-35.7||59.67|
|Return on Equity||0.0||-250.91|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||124.13||99.8|
|Div / share||0.0||0.0|
|Book value / share||-0.08||0.11|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3995361.0||1243086.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|PLX NM||Peers 39.22||PLX NM||Peers 22.43|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PLX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PLX's P/CF is negative making the measure meaningless.
|PLX NM||Peers 59.78||PLX NA||Peers 0.50|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PLX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PLX NM||Peers 12.10||PLX -7.40||Peers 166.85|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PLX's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, PLX is expected to significantly trail its peers on the basis of its earnings growth rate.
|PLX 15.65||Peers 264.78||PLX 110.79||Peers 540.54|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PLX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PLX significantly trails its peers on the basis of sales growth